If you're considering transcranial magnetic stimulation and want to know whether it can damage your brain, that's a reasonable question and it deserves a direct answer, not reassurance dressed up as information.
The short answer is no. There is no known physiological mechanism by which TMS causes brain damage, and no controlled clinical study has documented lasting neurological harm as a reproducible outcome. But understanding why that's true and being honest about what risks do exist is more useful than taking anyone's word for it.
This article covers what the research actually shows, where the fear comes from, and what genuine risks are worth knowing about before you decide whether TMS therapy is right for you.
Below, we cover:
Cognitive FX offers fMRI-guided accelerated TMS for treatment-resistant depression, with ~79% remission rates using precision targeting. Take our short quiz to see if you're a good fit, or call 385-334-6093 to speak with someone directly.
Transcranial magnetic stimulation works by delivering magnetic pulses through the scalp, inducing small electrical currents in targeted areas of the brain. Those currents increase blood flow in the targeted region, boost neurotransmitter activity, and increase the production of neurotrophins that support the health and growth of nerve cells. Nothing foreign enters the brain. TMS therapy works entirely by activating biological processes that are already there.
The intermittent theta burst stimulation (iTBS) protocol illustrates this well. Rather than imposing an artificial rhythm on the brain, iTBS delivers magnetic pulses in the same pattern the brain naturally produces during learning and memory consolidation. The brain recognizes this signal as its own and responds accordingly. The mechanism of action is biological amplification, not external force.
This form of brain stimulation works because depression disrupts normal neural activity in the prefrontal cortex. Under normal circumstances, this part of the brain functions like a regulatory switch: when negative thinking spirals, it dials things back down. Think of it as the brain's "snap out of it" switch. In major depression, that switch is weak and not very effective. But TMS treatment doesn't create a new circuit—it strengthens an already existing mechanism that isn't functioning properly.
You may have seen TMS described as a way to "reorganize your brain." This is inaccurate because TMS doesn't restructure a functioning brain. It provides a disorganized brain with the neuroplastic conditions to consolidate back toward how it's designed to work. TMS isn't reorganizing your brain. It's restoring normal brain function.
This is the question that matters most, and it has a clear answer rooted in basic neuroscience.
When a region of the brain is stimulated with repetitive transcranial magnetic stimulation (rTMS), the result is increased blood flow, enhanced responsiveness of nerve cells, and greater production of the proteins that support neuron health. Every one of those effects is constructive. The process of neuronal excitation that TMS produces is the same mechanism the brain uses during learning. This is a familiar signal for the brain, not a foreign one.
For TMS to cause brain damage, the electrical currents induced by the magnetic fields would need to trigger some toxic cascade that overwhelms or destroys brain cells. No such pathway exists. Even theoretically, there is no physiological mechanism of neuronal destruction from TMS stimulation.
The worst-case scenario of a TMS treatment course is that it doesn't improve your depression symptoms. Even if the coil were placed over a suboptimal brain region, the result would simply be increased brain activity in that region, not damage. A treatment that misses the target produces no benefit. It does not produce harm.
A related concern is whether TMS is a blunt instrument that damages regions that are fully functioning and don't need treatment. The answer requires two clarifications.
First, TMS is a targeted treatment. The coil is positioned over a specific part of the brain called the prefrontal cortex, and does not emit magnetic fields across the whole brain. This is one of the fundamental differences from electroconvulsive therapy (ECT), which induces whole-brain activity. The localized nature of TMS stimulation is a defining feature of how this form of neuromodulation works.
Second, even if adjacent healthy tissue receives some stimulation, the effect is the same: increased function, not harm. The mechanism doesn't change based on whether the tissue is dysfunctional or not.
It's also worth questioning the premise of "healthy" and "functioning" tissue in the context of depression. The entire prefrontal circuit underperforms in major depressive disorder, so stimulation anywhere in that area is appropriate, not excessive.
Headache · Scalp discomfort · Jaw clenching · Muscle twitching · Brief lightheadedness
Caused by trigeminal nerve activation near the scalp, not by effects on the brain itself
Tinnitus · Migraines
Most often reported during the first few sessions and diminish with continued treatment
Seizure
Risk is higher in patients with seizure history, which is a standard contraindication
Across decades of clinical research, no controlled study has documented lasting neurological damage from TMS as a reproducible outcome.
Transcranial magnetic stimulation has been studied as a depression treatment for decades. Its path to FDA approval in 2008 required comprehensive adverse event reporting across large clinical populations, and that reporting has continued in every major clinical trial since. Adverse effects must be reported in full; positive outcomes cannot obscure negative ones.
Across all of that accumulated data, no controlled study has documented lasting neurological damage from TMS as a reproducible outcome.
The most common side effects of TMS are short-term and mild:
These are the documented side effects of TMS across large patient populations in clinical trials spanning decades. Serious side effects are rare. The most significant is seizure, which occurs in fewer than 1 in 10,000 treatment sessions. The risk is higher in patients with a history of seizures or epilepsy, which is why those conditions are standard contraindications. Certain metallic implants near the treatment site, including cochlear implants and aneurysm clips, are also contraindications because the magnetic fields generated during treatment can interfere with these devices.
TMS is one of the most thoroughly safety-monitored medical treatments in psychiatry. The absence of a reproducible harm pattern across decades of FDA-required adverse event reporting is not a small piece of evidence.
This fear is understandable, and its source is almost always the same: confusion with electroconvulsive therapy (ECT).
ECT is the other major brain stimulation treatment for severe or treatment-resistant depression. ECT does carry a documented risk of memory impairment, particularly autobiographical memory loss around the treatment period. That risk is a direct consequence of ECT's mechanism: it works by inducing a generalized seizure across the whole brain under general anesthesia.
TMS and ECT share almost nothing mechanistically. TMS produces no generalized seizure, requires no anesthesia, and targets a localized region rather than the whole brain. The pathway that causes memory loss in ECT simply does not exist in TMS treatment. In the clinical data, no controlled study has documented memory loss as a reproducible adverse effect of TMS.
The data actually shows the opposite. Because the prefrontal cortex is involved in working memory and executive function, patients who respond to TMS frequently report improved attention, working memory, and executive function, alongside lifting depression symptoms. Cognitive fog is one of the most common complaints in treatment-resistant depression, and one of the first things patients notice improving after a successful treatment course.
If you've encountered the memory loss concern, it almost certainly traces back to ECT, a different treatment with a different mechanism and risk profile. For a detailed comparison, see our article on ECT vs. TMS: Compare Side Effects, Effectiveness, and Cost.
The two treatments differ fundamentally in mechanism, scope, and side effect profile
TMS and ECT share almost nothing mechanistically. The pathway that causes memory loss in ECT does not exist in TMS.
Search for TMS online, and these accounts are not hard to find. Reddit threads, Facebook groups, accounts from people who say TMS left them worse than before. Patients are right to bring these up, and they deserve a direct response rather than dismissal.
These experiences are not reflected in controlled clinical trial data across thousands of patients. Clinical trials are specifically designed to detect harm. All adverse effects must be reported, not just the positive outcomes. If lasting neurological damage from TMS were a real and reproducible phenomenon, it would appear consistently in that data. It has not.
One well-documented contributor to these accounts is attribution bias. A TMS treatment course is an intense experience: five to six weeks of treatment for standard rTMS, or a concentrated five-day course in an accelerated protocol. When something that significant happens and difficulties follow, the treatment becomes the natural explanation, whether or not there's an actual causal relationship. Attribution bias is a well-documented psychological pattern, and naming it here isn't dismissing anyone's experience. The difficulty these patients describe is real. The question is whether TMS caused it.
The TMS dip is also a real contributor. Roughly 20–25% of patients experience a temporary worsening of depression symptoms during or just after treatment, before improvement consolidates. For patients who don't know this is possible, that window can feel alarming and can be interpreted as permanent harm when it isn't. We cover whether TMS can make depression worse directly in a separate article.
The honest conclusion is that subjective reports and controlled clinical data diverge here. The absence of a reproducible harm pattern over decades of mandatory adverse event reporting is significant.
Some genuinely bad TMS outcomes have a more specific explanation than attribution bias. The patient wasn't an appropriate candidate, and the screening process didn't catch that before treatment began.
Bipolar disorder is the clearest example. The depressive phases of bipolar disorder can look clinically similar to major depressive disorder, and misdiagnosis or an incomplete psychiatric history means some patients begin TMS for what they and their healthcare provider believe is unipolar depression when the underlying condition is bipolar.
The brain's response to stimulation in bipolar disorder can differ substantially from its response in major depression, and outcomes can be unpredictable as a result. This is not a reason to avoid TMS, but patients need a thorough psychiatric evaluation before any treatment begins.
Other screening failures that contribute to poor outcomes include proceeding with patients who are actively suicidal and need crisis-level care first, or applying a depression protocol to a condition that requires a different stimulation target entirely. Obsessive-compulsive disorder (OCD), PTSD, and borderline personality disorder each have their own TMS protocols and stimulation sites. Treating them with a depression protocol applied to the wrong areas of the brain produces no real benefit and can leave patients convinced TMS harmed them when the actual problem was a mismatch between diagnosis and treatment design.
When TMS produces a genuinely bad outcome, inadequate screening is a far more likely explanation than neurological damage. The solution is a rigorous intake process, not avoidance of the treatment.
TMS is a safe outpatient procedure and does not cause brain damage, but there are genuine risks that patients should understand before beginning treatment.
Seizure is the most serious documented risk. It occurs in fewer than 1 in 10,000 sessions, and it can be effectively managed by standard contraindication screening. Patients with a history of seizures or epilepsy should not undergo TMS without specialist evaluation.
The TMS dip affects roughly 20–25% of patients. It is a temporary worsening of depression symptoms (not brain damage) that typically appears after the second or third treatment session and resolves as neuroplastic change consolidates. Knowing it can happen, and understanding why, makes a significant difference in how patients experience that window.
Short-term anxiety is occasionally reported during early sessions, particularly in patients with comorbid anxiety alongside their depression symptoms. This typically resolves as the treatment course progresses. For patients with anxiety-dominant presentations, discussing this potential side effect of TMS with your healthcare provider beforehand is important.
Non-response is a real outcome. Standard rTMS achieves full remission in roughly 30% of patients after weeks of treatment. Accelerated fMRI-guided protocols produce significantly higher rates, but no treatment works for everyone. The risk of TMS not helping you is real. The risk of it causing structural harm is not.
Treatment mismatch is also possible. TMS may simply not be the right approach for your specific presentation, which is why a qualified healthcare provider should be involved in the decision, not just the delivery, of treatment. If you have other mental health conditions alongside depression, those need to be part of the evaluation.
For a full breakdown of the side effects of TMS and their management, including over-the-counter options for headache management, we cover those in detail separately.
The discomfort patients feel and the effect on the brain are two separate events
The trigeminal nerve runs close to the scalp and gets activated by magnetic pulses during treatment
This nerve carries pain signals from the sinuses and teeth. When it fires, sensations register as jaw clenching, scalp discomfort, and mild headaches
These sensations are entirely peripheral and have nothing to do with what's happening in brain tissue
Increased blood flow to the targeted prefrontal cortex region, boosting nutrient and oxygen delivery
Enhanced neurotransmitter activity and increased production of BDNF, a protein that supports nerve cell health and growth
The theta burst pattern mimics the brain's own learning rhythms. The brain recognizes this signal as natural and responds positively
Repeated sessions strengthen underperforming neural circuits in the prefrontal cortex that regulate mood
The sensations patients describe during TMS come from scalp nerves, not brain tissue. The brain's response to stimulation is the opposite of harsh.
One of the main things that feeds concern about brain damage is how TMS actually feels during a session. Patients often describe it as jarring, with jaw clenching, mild headaches, and a sensation that seems to come from inside the skull.
The source of that sensation is the trigeminal nerve, which carries pain signals from the sinuses and teeth. This nerve runs close to the scalp and gets activated by the magnetic pulses during a TMS session. Because the trigeminal nerve is designed to alert you to problems like a tooth abscess or a sinus infection, when it fires, the sensation registers as a pain signal. That's what causes the jaw clenching and scalp discomfort that patients describe.
This is entirely a scalp-and-nerve experience. It has nothing to do with what's happening in brain tissue itself. The brain's response to TMS stimulation is constructive; the theta burst pattern is a signal the brain recognizes as natural, responds positively to, and is neurologically inclined to sustain. The discomfort patients feel during a session is peripheral, not a reflection of what's happening at the neuronal level.
For a detailed account of what each TMS session actually feels like from the patient's perspective, we cover that separately.
For patients who respond well to a first treatment course and are considering boosters or a second full course, the natural question is whether more TMS compounds any risk over time. It doesn't, and the clinical picture points in the opposite direction.
Every mechanism by which TMS works on the brain is constructive. There is no biological ceiling beyond which additional stimulation becomes harmful. The brain doesn't accumulate damage from repeated TMS exposure the way tissue can from, say, radiation. The process involved is the same mechanism used during learning and memory consolidation. Repetition reinforces it rather than degrading it.
Clinical data show that patients who return for a second treatment course after relapse consistently respond faster and achieve stronger outcomes than they did during their first course. The working explanation is that the first course lowers the threshold for neuroplastic change: the brain has been through the process and responds more readily the second time. There are no long-term side effects that accumulate with repetition in appropriately screened patients.
The genuine risks of repeated courses are identical to those of any single course: seizure in patients with relevant contraindications, and non-response. Neither increases with repetition.
For more on how long TMS results last and what follow-up care looks like, see our article on the long-term effects of TMS on the brain.
The safety of TMS treatment and its effectiveness are closely linked, and both depend on where the magnetic pulses are directed.
Standard rTMS uses an external landmark on the skull, typically the "5-cm rule," to estimate the location of the left dorsolateral prefrontal cortex (DLPFC), the region most consistently linked to mood regulation in major depression. This method is imprecise. Coil placement can vary by up to 2cm session to session, which means some sessions may stimulate the intended target accurately while others drift to adjacent regions.
This imprecision doesn't create a safety concern in the traditional sense. Stimulating adjacent prefrontal areas doesn't cause harm; those regions are also underperforming in depression. But imprecision does explain why standard rTMS achieves remission in only about 30–38% of patients. When the coil reliably reaches the optimal stimulation site, outcomes improve substantially.
FDA-approved neuronavigation systems address part of this problem by improving session-to-session consistency. The most precise approach combines neuronavigation with functional MRI data that maps each patient's brain activity before any stimulation takes place, identifying the exact location of the DLPFC rather than estimating it from external landmarks.
This is the approach used in the Stanford SAINT protocol and its equivalents, including Cognitive FX's accelerated TMS program.
Cognitive FX's accelerated fMRI-guided TMS addresses both efficacy and safety questions together. Before any stimulation begins, a functional MRI maps each patient's individual brain activity to locate the precise stimulation target in the prefrontal cortex, to within 1–2mm accuracy. FDA-approved neuronavigation then ensures the same location is reached reliably across all 50 sessions of the five-day treatment course.
The ideal candidate for accelerated TMS is an adult with major depressive disorder or treatment-resistant depression who has not found adequate relief from antidepressant medications. This is typically someone who has tried at least two different medications without sufficient response. If that describes your situation, the treatment is very likely to be both safe and appropriate for you.
Cognitive FX's screening process assesses all factors that could make TMS treatment unsuitable: history of seizures, epilepsy, cochlear implants, aneurysm clips or other metallic implants near the treatment site, active suicidality requiring crisis care, age under 18 or over 65, and psychiatric presentations that require different protocols, including bipolar disorder. These contraindications don't necessarily mean TMS is permanently off the table, but they may require additional specialist input before treatment proceeds. Patients who aren't appropriate candidates are told clearly.
Cognitive behavioral therapy is included in the treatment week alongside TMS sessions. Research shows this combination improves remission rates by approximately 19% compared to TMS alone and supports sustained improvement after the treatment course ends.
For patients who experience symptom recurrence, the fMRI targeting data from the initial treatment carry over to any future booster sessions, so no repeat scan is required. Initial treatment pricing includes a booster day, with discounted retreatment available beyond that.
Cognitive FX's program runs $7,000–$12,000, compared to $30,000 or more for the licensed Magnus SAINT™ product. Standard rTMS remains covered by most major insurers for qualifying patients; the accelerated protocol is self-pay. Cognitive FX's program is an off-label equivalent of the SAINT protocol (not the licensed Magnus SAINT™ product) using the same dosage, schedule, and iTBS delivery, with fMRI analysis performed in-house by Cognitive FX's neuroscientist and physician.
| Standard rTMS | Cognitive FX (fMRI-Guided) | |
|---|---|---|
| Targeting method | Anatomical landmarks on the scalp; margin of error up to 2cm | fMRI maps individual brain activity; accuracy within 1–2mm |
| Session navigation | Manual coil placement; varies session to session | FDA-approved neuronavigation; same exact spot every session |
| Schedule | 1 session/day over 4–6 weeks | 50 sessions in 5 days (equivalent total dose) |
| Pulse type | Standard repetitive pulses; 30–40 min per session | Intermittent theta burst (iTBS); ~10 min per session |
| CBT included | Typically not part of TMS protocol | Built into treatment week; improves remission rates ~19% |
| Remission rate | ~30% full remission | ~79% remission with fMRI-guided targeting |
| Booster plan | Varies by clinic; often no formal follow-up | fMRI data carries forward; booster day included in pricing |
| Cost | Often covered by insurance | $7,000–$12,000 (self-pay); vs. $30,000+ for Magnus SAINT™ |
CFX's program is an off-label equivalent of the SAINT protocol, not the licensed Magnus SAINT™ product. Protocols are equivalent in dosage, equipment, and schedule.
To understand whether you're a likely candidate for treatment, take our short quiz or call 385-334-6093 to speak with someone directly.
Dr. Mark D. Allen holds a Ph.D. in Cognitive Science from Johns Hopkins University and received post-doctoral training in Cognitive Neuroscience and Functional Neuroimaging at the University of Washington. As a co-founder of Cognitive Fx, he played a pivotal role in establishing the unique and exceptional treatment approach. Dr. Allen is renowned for his pioneering work in adapting fMRI for clinical use. His contributions encompass neuroimaging biomarkers development for post-concussion diagnosis and innovative research into the pathophysiology of chronic post-concussion symptoms. He's conducted over 10,000 individualized fMRI patient assessments and crafted a high-intensity interval training program for neuronal and cerebrovascular recovery. Dr. Allen has also co-engineered a machine learning-based neuroanatomical discovery tool and advanced fMRI analysis techniques, ensuring more reliable analysis for concussion patients.
Deciding to try TMS means agreeing to let magnetic pulses change how your brain works. That's not a small thing to sign up for, and wanting to know what that means for your brain in the long run is...
While antidepressant medications remain the most common first-line treatment for depression, research shows they only work for about one-third of patients and often come with unpleasant side effects...
Traditional antidepressant medications involve a trial period of weeks or months before it can be determined whether or not they are working. If a medication doesn’t work — and it’s been shown that ...
If you’re considering transcranial magnetic stimulation (TMS) therapy, you may be concerned about its side effects and whether the benefits outweigh any risks.
If you’re considering transcranial magnetic stimulation (TMS) therapy, one of the first and most important questions you’re likely to ask is: “Is TMS safe?”
If you’re considering transcranial magnetic stimulation (TMS) therapy, it’s essential to understand the potential pros and cons of the treatment. Fortunately, for those suffering from major...
